HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).

Brown researchers will look into how a drug originally developed to treat HIV may reduce age-related inflammation.

In this open-label trial with a 2-by-4 factorial design, we randomly assigned children with HIV who had first-line treatment failure to receive second-line therapy with tenofovir alafenamide fumarate ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...